Phase 3 Pancreatitis Trial, Completed NCT01014390 Sponsor: Boston Scientific Corporation Condition: Pancreatitis
Back to Pancreatitis

Trial results

AI generated results summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

According to the results reported on ClinicalTrials.gov, this trial enrolled 187 participants, all of whom received a device called the WallFlex Biliary RX Fully Covered (FC) Stent System — a type of tube placed in the bile duct to help keep it open. Of the 187 people who started the trial, 177 completed it, and 10 did not complete it (the reasons were not detailed in the reported data). The trial was a single-group study, meaning everyone received the same device with no comparison group. The main thing the trial set out to measure was called "stent removability" — specifically, whether the stent could be removed using an internal camera procedure (endoscopy) without serious problems related to the removal, tracked from the time of removal up to one month afterwards. The reported data shows that out of the 187 participants who started, 132 participants had their stent removal recorded as meeting this definition. No further breakdown of the outcome — such as what happened in the remaining cases or why the numbers differ — was included in the data reported to ClinicalTrials.gov. There were no secondary outcome measure results included in the submitted data. It is worth noting that this was a single-arm trial (everyone received the same treatment), so the reported numbers describe what was observed in this one group only, with no direct comparison to another treatment or device. The reported data shows only what was measured and counted in this specific study population. These are the results as reported to ClinicalTrials.gov. They are not medical advice — always discuss what they mean for you with your doctor.

These are the results as reported to ClinicalTrials.gov, not medical advice. Verify independently with the trial site and discuss what they mean for you with your doctor.

Phase 3 Pancreatitis Trial, Completed

NCT01014390
Completed Phase 3 🇦🇺 Australian site

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You are 18 years of age or older
  • You are willing and able to follow the study procedures and sign a consent form to take part
  • You have been diagnosed with chronic pancreatitis, have had a liver transplant in the past, or have had another abdominal surgery before (including gallbladder removal)
  • You need an ERCP procedure with a stent placed for one of these reasons: a bile duct blockage causing symptoms (such as jaundice, persistent bile buildup, or a bile duct infection) confirmed by imaging; a bile duct narrowing confirmed by imaging; or replacing a previous plastic stent used to treat a non-cancerous narrowing

Who may not be able to join:

  • The narrowed area in the duct cannot be opened wide enough to fit the delivery device through
  • The duct has a hole or tear in it
  • The ducts inside the liver are too small for the stent
  • Endoscopic procedures (procedures using a camera passed through the mouth) are not medically suitable for you
  • The bile duct narrowing is caused by cancer
  • The bile duct narrowing has a non-cancerous cause other than chronic pancreatitis, liver transplant, or previous abdominal surgery
  • The narrowing is located less than 2 cm from where the bile duct splits into two branches
  • You have a blocked or narrowed duodenum (the first part of the small intestine) causing your stomach to empty slowly
  • You have previously had a self-expanding metal stent placed in your bile duct
  • Imaging or endoscopy suggests the narrowing may be caused by reduced blood supply to the bile duct (confirm with trial site)
  • You have a known connection or opening between your bile duct and another structure (bile duct fistula)
  • You have a known allergy or sensitivity to any materials used in the stent or delivery device
  • You have taken part in another clinical research study within the 90 days before signing consent, or are currently in another study
  • (For chronic pancreatitis patients only) Your bile duct symptoms are related to a current episode of acute pancreatitis
  • (For patients who have had abdominal surgery only) You have previously had part of your liver removed, or you have had a liver transplant
  • (For liver transplant patients only) Your transplant came from a living donor

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 3: approximately ~65% of drugs entering this phase reach regulatory approval, based on published industry-wide historical data. This is not specific to this trial.
Phase success rates shown are historical industry-wide averages based on published data. They are not a prediction for this specific trial or your individual situation.

Contact this trial

Australian sites

Westmead Hospital, Westmead, New South Wales

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Completed
Phase
Phase 3
Sponsor
Boston Scientific Corporation
Registry
ClinicalTrials.gov
Start date
1 December 2009
Est. completion
1 November 2012

Where this trial is recruiting

🇦🇺 Australia 🇦🇹 Austria 🇧🇪 Belgium 🇨🇦 Canada 🇨🇱 Chile 🇫🇷 France 🇩🇪 Germany 🇮🇳 India 🇮🇹 Italy 🇳🇱 Netherlands 🇪🇸 Spain

1 site(s) in Australia. Confirm current status and contact details directly with the trial site.

Primary endpoints

Stent Removability

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov